secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-048942
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics prices $40M pre-funded warrant offering; lead investor Coastlands Capital
--------------------------------------------------------------------------------

- Pre-funded warrants to purchase 74,780,300 common shares at $0.5349/warrant; exercise price $0.0001/share.
- Gross proceeds ~$40M; net proceeds ~$37.1M after underwriting discounts and offering expenses.
- Offering led by Coastlands Capital with participation from Gilead, OrbiMed, Perceptive Advisors.
- Expected closing date February 13, 2026; net proceeds for product development and general corporate purposes.
- Pre-funded warrants immediately exercisable; beneficial ownership capped at 4.99% (holder can elect up to 19.99%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/0001193125-26-048942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/d85184d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-048942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer